# Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water

> **NCT00871806** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Commercial tablet with water
- **DRUG:** ODT #1 without water
- **DRUG:** ODT #2 without water
- **DRUG:** ODT #1 with water
- **DRUG:** ODT #2 with water

## Key facts

- **NCT ID:** NCT00871806
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871806, "Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00871806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*